Royalty Pharma plc (RPRX)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2018	FY 2016	FY 2015
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Cystic Fibrosis Franchise Revenue	819.92M	826.21M	852.31M
Cystic Fibrosis Franchise Revenue Growth	-0.76%	-3.06%	5.36%
Evrysdi Revenue	213.41M	224.43M	97.74M
Evrysdi Revenue Growth	-4.91%	129.61%	-
Trelegy Revenue	149.91M	146.92M	128.05M
Trelegy Revenue Growth	2.04%	14.74%	121.04%
Tremfya Revenue	149.47M	147.14M	149.72M
Tremfya Revenue Growth	1.59%	-1.72%	36.36%
Tysabri Revenue	120.29M	124.82M	167.54M
Tysabri Revenue Growth	-3.63%	-25.50%	-19.13%
Imbruvica Revenue	-	131.09M	173.16M
Imbruvica Revenue Growth	-	-24.30%	-44.31%
Other Products Revenue	636.85M	548.82M	629.24M
Other Products Revenue Growth	16.04%	-12.78%	-0.17%
Total Income from Financial Royalty Assets	2.23B	2.15B	2.20B
Total Income from Financial Royalty Assets Growth	3.77%	-2.20%	3.42%
Revenue from Intangible Royalty Assets	-	-	835.00K
Revenue from Intangible Royalty Assets Growth	-	-	-97.77%
Other Royalty Income	-	-	155.97M
Other Royalty Income Growth	-	-	108.97%
Other Royalty Income and Revenue	119.28M	114.15M	156.80M
Other Royalty Income and Revenue Growth	4.49%	-27.20%	39.85%
Revenue (Other)	-213.41M	-224.43M	-97.74M
Revenue (Total)	2.35B	2.26B	2.35B
Revenue (Total) Growth	3.81%	-3.86%	5.24%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2018	FY 2016	FY 2015
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Portfolio Receipts	3.12B	2.80B	3.05B
Portfolio Receipts Growth	11.45%	-8.11%	9.30%

Updated Nov 5, 2025. Data Source: Fiscal.ai.